Michael Lefenfeld net worth and biography

Michael Lefenfeld Biography and Net Worth

Director of Immunome

Michael Lefenfeld is the president and chief executive officer of Cyanco, the leading global supplier of reagents and technologies which enable commercial mining of precious metals – Gold and Silver. He is also the co-founder and former chief executive officer of SiGNa Chemistry, a global manufacturer of highly-active, environmentally friendly chemicals. SiGNa’s products are used to improve production processes in the energy recovery, petrochemical refining and chemical manufacturing industries. His work has led to safer industrial environments, better medical technologies and more effective, affordable energy solutions. Prior to SiGNa, Lefenfeld developed and commercialized several new technologies, launching and selling three companies by age 30. Lefenfeld holds more than 50 patents in medical devices, controlled release, electronics, chemical reactivity and information technology. After earning a bachelor’s degree in chemical engineering at WashU in 2002, Lefenfeld, a resident of New York City, earned a master’s in chemistry at Columbia University and an executive education certificate at Stanford University’s Graduate School of Business.

What is Michael Lefenfeld's net worth?: The estimated net worth of Michael Lefenfeld is at least $938.73 thousand as of May 24th, 2021. Mr. Lefenfeld owns 46,726 shares of Immunome stock worth more than $938,725 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Lefenfeld may own. Learn More about Michael Lefenfeld's net worth.
How do I contact Michael Lefenfeld?: The corporate mailing address for Mr. Lefenfeld and other Immunome executives is , , . Immunome can also be reached via phone at 610-321-3700 and via email at [email protected]. Learn More on Michael Lefenfeld's contact information.
Has Michael Lefenfeld been buying or selling shares of Immunome?: Michael Lefenfeld has not been actively trading shares of Immunome during the last ninety days. Most recently, on Wednesday, May 26th, Michael Lefenfeld bought 1,335 shares of Immunome stock. The stock was acquired at an average cost of $19.03 per share, with a total value of $25,405.05. Following the completion of the transaction, the director now directly owns 22,822 shares of the company's stock, valued at $434,302.66. Learn More on Michael Lefenfeld's trading history.
Who are Immunome's active insiders?: Immunome's insider roster includes Jean Bienaime (Director), Jack Higgins (Insider), Robert Lechleider (Insider), Michael Lefenfeld (Director), Michael Rapp (Director), Max Rosett (CFO), Purnanand Sarma (CEO), Clay Siegall (CEO), Philip Tsai (CTO), and Bruce Turner (Insider). Learn More on Immunome's active insiders.
Are insiders buying or selling shares of Immunome?: In the last twelve months, Immunome insiders bought shares 5 times. They purchased a total of 311,400 shares worth more than $2,369,895.00. The most recent insider tranaction occured on June, 3rd when Director Jean Jacques Bienaime bought 5,000 shares worth more than $46,900.00. Insiders at Immunome own 7.7% of the company. Learn More about insider trades at Immunome.
Information on this page was last updated on 6/3/2025.

Michael Lefenfeld Insider Trading History at Immunome

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/26/2021	Buy	1,335	$19.03	$25,405.05	22,822
5/24/2021	Buy	600	$17.80	$10,680.00	46,726

Michael Lefenfeld Buying and Selling Activity at Immunome

Immunome Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Today's Range

Now: $20.09

$18.91

$20.40

50 Day Range

MA: $15.98

$11.34

$20.09

2 Week Range

Now: $20.09

$5.15

$20.40

Volume

1,531,875 shs

Average Volume

1,267,980 shs

Market Capitalization

$1.84 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17